... associated Supplementary Protection Certificate (SPC)) protected rivastigmine, a drug used for the treatment of Alzheimer's disease. The Court of Appeal held the patent to be invalid on the ground of obviousness and criticised the over-reliance on ...
http://www.jdsupra.com/legalnews/news-from-abroad-uk-court-of-appeal-uph-25218/
http://www.jdsupra.com/legalnews/news-from-abroad-uk-court-of-appeal-uph-25218/
No comments:
Post a Comment